Sort
8,912 grants matching “sars cov 2”
International epidemiology Databases to Evaluate AIDS (IeDEA) Southern Africa.
$3,060,068Eliane Rohner · Universitat Bern · U01 · FY2024 · AI
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
$3,057,531Ignacio E. Sanz · Emory University · U54 · FY2023 · CA
Centers for Research on Structural Biology of Infectious Diseases: SARS-CoV-2
$3,052,532Karla Satchell · Northwestern University At Chicago · N01 · FY2024 · AI
Cardiovascular Genomics and Bioinformatics projects
$3,050,975Andrew Johnson · National Heart, Lung, And Blood Institute · ZIA · FY2023 · HL
Role of the Non-canonical Inflammasome in SARS-CoV-2-mediated Pathology and Coagulopathy
$3,046,145Amal O Amer · Ohio State University · P01 · FY2024 · AI
Project 4: Nuclease Inhibitors for Viruses of Pandemic Concern
$3,040,167Hideki Aihara · University Of Minnesota · U19 · FY2022 · AI
SARS-CoV-2 initiation and acceleration of AD pathology in the setting of endogenous and exogenous risk factors
$3,039,032Ananth V Annapragada · Baylor College Of Medicine · RF1 · FY2025 · NS
COVID-19: immune response and systems vaccinology
$3,036,975Lothar Hennighausen · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable Populations
$3,032,553Marianna K Baum · Florida International University · U01 · FY2020 · DA
CRDF Coordinating Center: Logistics Support Under CRDF Global
$3,020,000Samuel Howerton · National Cancer Institute · Y01 · FY2021 · CA
ADJUVANT COMPARISON AND CHARACTERIZATION
$3,018,059Bali Pulendran · Stanford University · N01 · FY2024 · AI
MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR): SARS-CoV-2 VACCINE RESEARCH RELATED ACTIVITIES
$3,008,705Timothy Stedman · American Type Culture Collection · N01 · FY2021 · AI
MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESEARCH REPOSITORY (MID BRR) - SARS-CoV-2 THERAPEUTICS RESEARCH RELATED ACTIVITIES
$3,008,705Timothy Stedman · American Type Culture Collection · N01 · FY2021 · AI
Sirtuins and nuclear receptors in aging and age-associated diseases
$3,007,589Xiaoling Li · National Institute Of Environmental Health Sciences · ZIA · FY2021 · ES
SARS-CoV-2 Screening and Diagnostic testing for return to K-12 schools
$3,004,526Kanecia Obie Zimmerman · Duke University · OT2 · FY2021 · HD
Role of the Non-canonical Inflammasome in SARS-CoV-2-mediated Pathology and Coagulopathy
$3,004,517Amal O Amer · Ohio State University · P01 · FY2025 · AI
Unravelling immunoregulatory circuits of tissue inflammation
$3,000,357Behdad Afzali · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
THE PURPOSE OF THIS MODIFICATION IS TO EXTEND LINE ITEM 1005 TO 1/31/21 FOR CONTINUING ENTREPRENEURIAL SERVICES FOR THE COVID-19 PANDEMIC.
$3,000,026Elias Caro · · N02 · FY2021 · HL
Mass Tag PCR Detection of Respiratory Pathogens
$3,000,000Columbia University Health Sciences · UC1 · FY2004 · AI
Mechanisms and Duration of Immunity to SARS-CoV-2
$2,997,978Scott Dexter Boyd · Stanford University · U54 · FY2023 · CA
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** IT NOW APPEARS CERTAIN THAT SARS-COV-2 WILL PERSIST IN ANIMALS AS LONG AS IT IS PREVALENT IN HUMANS. THE IMPLICATIONS OF MULTIPLE MAMMAL SPECIES CONTRACTING SARS-COV-2 ARE UNCLEAR, BUT MOUNTING EVIDENCE SUGGESTS THAT SOME ANIMALS MAY EXPERIENCE FATAL DISEASE, AND THAT ANIMAL SPECIES WILL SERVE BOTH AS STABLE RESERVOIRS OF VIRAL VARIANTS THAT WERE PREVIOUSLY DOMINANT IN HUMANS, AND AS NEW RESERVOIRS FOR NEW VARIANTS. MANY OF THESE NEW RESERVOIRS ARE COMMON WILDLIFE SPECIES, SUCH AS WHITE-TAILED DEER, DEER MICE AND RED FOX, WHICH OCCUR IN RELATIVELY HIGH ABUNDANCES IN SOME SYSTEMS AND HIGHLIGHT PATHWAYS OF SECONDARY SPILLOVER TRANSMISSION TO HUMANS LIVING IN CLOSE PROXIMITY. TO UNDERSTAND THE FUTURE OF SARS-COV-2 IN MAMMAL COMMUNITIES, THIS PROJECT WILL ADVANCE OUR CURRENTLY LIMITED CAPACITY TO PREDICT ANIMAL HOST SPECIES, NOVEL ZOONOTIC VARIANTS, AND THE POTENTIAL INTERACTIONS AMONG MULTIPLE SPECIES THAT COMPRISE MAMMAL COMMUNITIES. TO ACHIEVE THIS, THIS PROJECT INTEGRATES LEADING EDGEADVANCES IN ARTIFICIAL INTELLIGENCE, VIROLOGY, AND ECOLOGICAL THEORY IN FOUR SPECIFIC AIMS: AIM 1 MAKES PREDICTIONS ABOUT FUTURE ZOONOTIC VARIANTS OF SARS-COV-2 AND THEIR EVOLUTIONARY TRAJECTORIES BY ADVANCING METHODS IN CONTROLLED GENERATIVE AI. AIM 2 PREDICTS WHICH PARTICULAR MAMMALIAN SPECIES ARE SUITABLE HOSTS FOR EXISTING AND FUTURE ZOONOTIC VARIANTS, EXTENDING PREDICTIONS EVEN TO SPECIES FOR WHICH HOST CELL RECEPTOR (ACE2) SEQUENCES ARE STILL UNKNOWN. AIM 3 CONDUCTS SAFE AND EFFICIENT EMPIRICAL VALIDATIONS OF PREDICTIONS MADE IN AIMS 1 AND 2 BY TESTING CELL ENTRY USING A PSEUDOTYPED VIRUS PLATFORM FOR A SUBSET OF ZOONOTIC VARIANTS AND ANIMAL CELL RECEPTORS. AIM 4 ADVANCES THEORY FOR DISEASE TRANSMISSION IN WILDLIFE COMMUNITIES BY BUILDING A FRAMEWORK THAT ACCOUNTS FOR SPECIES DISTRIBUTIONS, THEIR ECOLOGICAL INTERACTIONS (SUCH AS PREDATION AND COMPETITION), AND FINE-SCALE CONTACT PATTERNS THAT INFLUENCE TRANSMISSION AMONG INDIVIDUAL ANIMALS. TOGETHER THESE METHODS ENABLE SPATIALLY EXPLICIT PREDICTIONS ABOUT SARS-COV-2 DYNAMICS IN MAMMAL COMMUNITIES. THIS MODEL WILL BE APPLIED TO THE NORTHEASTERN FOREST COMMUNITY USING 30 YEARS OF DATA FOR MULTIPLE MAMMAL SPECIES AND ONGOING SARS-COV-2 SURVEILLANCE. COLLECTIVELY, THE TOOLS DEVELOPED IN THIS PROJECT WILL LEAD TO THE RAPID PREDICTION AND VALIDATION OF ANIMAL HOSTS FOR CURRENT AND FUTURE VARIANTS OF SARS-COV-2. GIVEN THE PERSISTENT AND GROWING RISK OF ZOONOTIC EMERGENCE FROM ANIMAL HOSTS, THE INNOVATIONS DEVELOPED IN THIS PROJECT WILL ADVANCE RISK ASSESSMENT CAPACITY FOR WILDLIFE, DOMESTIC ANIMALS, AND HUMANS BY HELPING TO PREDICT AND TARGET PARTICULAR VIRUSES, THEIR VARIANTS, AND THEIR MULTIPLE HOST SPECIES, WHILE ALSO INTEGRATING THE DYNAMIC ECOLOGICAL CONTEXT IN WHICH SPECIES INTERACTIONS AND TRANSMISSION CULMINATE TO INFORM ZOONOTIC RISK IN COMPLEX SYSTEMS.
$2,995,370University Of South Florida · · FY2023 · National Institute of Food and Agriculture
Inhibiting Viral Macrodomains Using Structure-Based Design
$2,988,130James Solomon Fraser · University Of California, San Francisco · U19 · FY2022 · AI
Vasculitis and Translational Medicine
$2,975,025Peter Grayson · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2024 · AR
Integrative Bioinformatics
$2,970,345Jian-Liang Li · National Institute Of Environmental Health Sciences · ZIC · FY2023 · ES
Paramyxoviruses as Vaccine Vectors Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
$2,955,452Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI